Further, based on analysis by Gray et al. [31], the expectation is that approximately 15–32% of patients with EGFR-mutant NSCLC do not shed enough ctDNA into circulation to be detected by the current available assays, thus leading to false-negative results. This evidence concerns the gene EGFR and non-small cell lung carcinoma.